To Compare the Response Rate of Noradrenaline vs. Terlipressin in Hepatorenal Syndrome in Patients With Acute on Chronic Liver Failure

• Status: Completed
• Trial end date: 2017-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Continous infusion of nor adrenaline + albumin Continous infusion of terlipressin + albumin Response will assessed at every 48 hour (i) Complete response: Regression of acute kidney injury stage with reduction of S. Cr within 0.3 mg/dl of baseline (ii) Partial response: Regression of acute kidney injury stage with reduction of S. Cr to ≥0.3 mg/dl above baseline (iii) No response: No regression of acute kidney injury

Treatment will be extended until reversal of HRS (decrease in creatinine below 1.5 mg/dL) or for a maximum of 7 days after rescue treatment will be followed.

If intolerant to terlipressin, excluded from study and rescue treatment will be given in form of noradrenaline or octreotide and midodrine.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institute of Liver and Biliary Sciences, India
• Treatments: Epinephrine; Epinephryl borate; Lypressin; Norepinephrine; Racepinephrine; Terlipressin

Criteria

Inclusion Criteria:

1. Patients with acute on chronic liver failure presenting with hepatorenal syndrome

2. Patients consented for the study protocol by signing the informed consent.

Exclusion Criteria:

1. Age less than 18 years

2. Decompensated cirrhotics

3. Evidence of chronic kidney disease

4. Patients undergoing renal replacement therapy (hemo-dialysis/renal transplantation).

5. Post liver transplantation patients.

6. History of coronary artery disease, ischaemic cardiomyopathy, ventricular arrhythmia, or peripheral vascular disease.

7. Patients with obstructive uropathy.

8. Patient who withdrew or non complaint to the study protocol.